Phage Therapy, Lysin Therapy, and Antibiotics, a Trio Due to Come

Dear Colleagues,

Conventional antimicrobials have been for decades the panacea for controlling pathogenic and non-desirable bacteria, ever since the introduction of the “magic-bullet” idea by Paul Ehrlich at the beginning of the XXth century. The prescription, the missuse and most importantly the genesis of several spontaneous mutants has led to the emergence of multiresistant bacteria to antibiotics, commonly used in the treatment of current and deadly forms of diseases both in humans and other animals, to such an extent that practitioners often run out of effective prescriptions. Combination of therapies or treatments, based on different compounds is generally recognized as the more effective strategy to fight resistances. Bacteriophages (phages) are viruses that kill bacteria in a quite specific manner. Proposed a century ago, and then forgotten in western countries, phages and their lysins have emerged recently in the West as promising alternative against pathogenic bacteria, and have to walk together with the current chemotherapy including antibiotics, to design new combined strategies for the control of non-desirable bacteria, particularly those exhibiting multiresistant phenotypes.

This Special Issue of "Phage therapy, lysin therapy, and antibiotics, a trio due to come" deals with the more recent advances in these combined therapies. The issue welcomes various submission types, such as original research papers, short communications, reviews, case reports, and perspectives.

• Potential topics for this Special Issue include, but are not limited to:
• Search for phages and lysins with new mechanisms of action
• Advanced phage and lysins therapies or combined therapies with antibiotics in clinics and veterinary, including aquaculture (particularly in intensive cultures)
• Phage and lysin treatments for food-biopreservation
• Phage and lysin treatments against phytopathogenic bacteria
• Phage treatment of drinking water reservoirs
• Phage treatment of sewage waters
• Environment control of multidrug resistant bacteria: reversion of multidrug resistances
• Tailor-made phages and lysins designed for specific purposes: new genetically modified phages and lysins
• Precise formulation of phages for a variety of uses on/off clinics
• Prevention of resistances to phages and lysins

Prof. Dr. Tomas. G. Villa
Prof. Carmen Sieiro
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.